INTRODUCTION

Mefloquine
(MQ) is a synthetic quinoline-derivative antimalarial drug structurally related to quinine that exhibits idiosyncratic central nervous system toxicity [1] . In double blinded studies, a range of neuropsychiatric adverse reactions-including strange or vivid dreams, dizziness, vertigo, concentration impairment, anxiety, and depression-are reported by 29-77% of MQ users at prophylactic doses of 250 mg weekly [2, 3] . Neuropsychiatric adverse reactions may occur early during use-frequently within the first three doses-and may even occur after only a single dose [4, 5] .
As evidenced by a recent retrospective cohort study, among those reporting adverse reactions to MQ, 21% of those reporting nightmares and 33% of those reporting cognitive dysfunction identified these adverse reactions as persisting over 3 years after use [6] . A boxed warning added to the United States (US) drug label (DL) in 2013 emphasizes that MQ may cause ''neuropsychiatric adverse reactions that can persist after mefloquine has been discontinued''. Prescribing guidance in the US DL now recommends to discontinue (DC) MQ at the onset of neuropsychiatric symptoms, as certain of these may suggest an individual risk of ''more serious psychiatric disturbances or neurologic adverse reactions'' that could occur with continued use of the drug. The US DL now cautions that psychiatric reactions ''ranging from anxiety, paranoia, and depression to hallucinations and psychotic behavior can occur with mefloquine use'' and ''have been reported to continue for months or years after mefloquine has been stopped''. The US DL now also cautions that certain neurological reactions ''have been reported to be permanent in some cases'' [7] .
The highly prescriptive safety guidance in the current DL reflects its gradual evolution over the prior quarter century. At the time of the US licensing of MQ in 1989, the original DL instructed physicians only that, ''[d]uring prophylactic use, if signs of unexplained anxiety, depression, restlessness or confusion are noticed, these may be considered prodromal to a more serious event. In these cases, the drug must be discontinued'' [8] . This language was subtly updated in 2002, changing the previously exclusive list of prodromal reactions to an illustrative list by stating, ''if psychiatric symptoms such as [emphasis added] acute anxiety, depression, restlessness or confusion occur, these may be considered prodromal to a more serious event. In these cases, the drug must be discontinued and an alternative medication should be substituted'' [9] .
The 2002 DL update introduced potential ambiguity as to whether US physicians were to counsel patients that the onset of any psychiatric symptom should be considered prodromal and prompt DC, or merely that those explicitly listed and similar reactions should be considered prodromal and prompt DC. The 2013 DL update likewise noted, ''[d]uring prophylactic use, the occurrence of psychiatric symptoms such as acute anxiety, depression, restlessness or confusion suggest a risk for more serious psychiatric disturbances or neurologic adverse reactions [emphasis added]. In these cases, the drug should be discontinued and an alternative medication should be substituted''. The 2013 boxed warning addressed any remaining potential ambiguity in this illustrative list by emphasizing simply, ''During prophylactic use, if psychiatric or neurologic symptoms occur, the drug should be discontinued and an alternative medication should be substituted '' [7] . In the US, in the case of certain drugs ''that pose a serious and significant public health concern'', the FDA may require specific safety guidance be communicated directly to patients in the form of a medication guide (MG) provided at the time of dispensing, which complements counseling received by the patient at the time of prescribing [12] . The FDA requires a MG when it determines patient adherence to directions for use are considered crucial to a drug's effectiveness; when the drug has serious risks relative to benefits; or when patient safety guidance in the MG could help prevent ''serious adverse effects'' [12] .
Consistent with this final rationale, the MG for MQ was first required by the FDA in 2003 [13] .
The current US MG explicitly lists certain psychiatric or neurologic adverse reactions for which patients are recommended to consult with a physician or healthcare provider (CP) prior to taking their next dose. Although the US boxed warning clearly recommends DC ''if psychiatric or neurologic symptoms occur'', as is the case with the MG, only certain specific neurologic or psychiatric adverse reactions are explicitly listed in the current US DL with a recommendation to DC [7] .
The 
METHODS
Prescribing and Patient Safety Documents
Prescribing safety guidance in the UK and IRL is provided in a document referred to as a Where one or more adverse reactions were listed ambiguously within a paragraph that contained a particular recommendation associated with a smaller list of adverse reactions or a more general description of an adverse reaction, the recommendation was deemed to apply to that term. For example, based on the following paragraph in the US DL, a recommendation to DC was deemed to apply to the adverse reactions dizziness, vertigo, tinnitus, and loss of balance.
''Neurologic symptoms such as dizziness or vertigo, tinnitus, and loss of balance have been reported. These adverse reactions may occur early in the course of mefloquine use and in some cases have been reported to continue for months or years after mefloquine has been stopped. Dizziness or vertigo, tinnitus, and loss of balance have been reported to be permanent in some cases. During prophylactic use, if neurologic symptoms occur, the drug should be discontinued and an alternative medication should be substituted'' [7] .
Where the text referred explicitly to an adverse reaction occurring only in the context of a pre-existing condition or contraindication, this was not included in this analysis. Similarly, if an adverse reaction was described only in a section of the text describing guidance applicable prior to starting MQ, without referencing explicitly that the adverse reaction could also be caused by MQ, it was not included in this analysis. Likewise, if an adverse reaction appeared only in a 
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RESULTS
At the time of analysis, the drug remained licensed in all six countries, although the innovator product had been withdrawn from the US as of 2011 and from CAN as of 2013 [15, 16] . to physicians for these specific adverse reactions in the DL (Table 3) .
DISCUSSION
Agreement in Prescribing and Patient
Guidance
This analysis finds complete international agreement across the six countries in corresponding prescribing and patient safety 
Changes in physical activity
Restlessness/feeling restless DC CP DC DC DC DC DC CP DC CP DC CP In contrast, this analysis finds only partial international agreement across two or more countries in corresponding prescribing and patient safety guidance to CP or DC in response to specific neurologic and psychiatric adverse reactions within an additional seven HLGTs. These include the very common adverse reaction of abnormal dreams, included within the HLGT sleep disorders and disturbances. The common, occurring in C1/100-1/10 of prophylactic users.
Cognitive and attention disorders and disturbances
Disturbance with attention DC DC
Deliria (including confusion)
Confusion/feeling confused DC CP DC DC DC DC DC CP DC CP DC CP
Dementia and amnestic conditions
Relevance of Findings
Demand for MQ has been negatively impacted due to increased awareness of the drug's potential to cause lasting central nervous system toxicity [1] -an outcome which, despite numerous proposed pathophysiological mechanisms [17] [18] [19] [20] , remains poorly understood. Amidst losses in market share to safer and better tolerated antimalarial drugs, the innovator, Roche, has elected to withdraw to include IRL, Germany, and Denmark [21] . Although there are concerns the drug may soon be withdrawn from other countries for similar reasons [22] , MQ is likely to remain available internationally in generic forms for some time.
This analysis provides important insights that may be relevant during patient counseling and in the consideration of potential future improvements to MQ safety guidance. 
CONCLUSIONS
MQ prescribing guidance in a growing number of countries now recommends DC at the onset of any neuropsychiatric adverse reaction. This analysis has identified certain common and very common neuropsychiatric adverse reactions to MQ for which DC is explicitly recommended and for which there is complete or partial international agreement these reactions be specifically listed in both prescribing and patient guidance.
The results of this analysis suggest opportunities for physicians in these countries to improve patient counseling by specifically emphasizing the need to DC at the onset of these adverse reactions. The results of this analysis also suggest opportunities for international drug regulators to clarify language in future updates to remaining MQ DLs and MGs to better reflect national risk-benefit considerations for continued use of the drug.
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